Slingshot members are tracking this event:

Exelixis’ (EXEL) Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 21, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cabometyx, Cabozantinib, Hepatocellular Carcinoma